home free of genetically modified organisms, announces the new Mini Biscuits gluten-free control of the project: an allergy-friendly company that supports the movement of genetically modified organisms is not only a label, and the campaign

Today announced that the Windham, New Hampshire (PRWEB) 23 يناير 2012

free home and treats you can trust, he did not become a non-GM in order to control the project (http://www.nongmoproject.org/product- verification /) in its latest line of gluten-sensitive mini-cookies for free, and friendly. Individual, including chocolate chip and chocolate chocolate chips to grocery stores and catering. As HomeFrees approved a new small vanilla cookies, which were the best food in the last round of new natural products in the Middle in 2011, as well as the recently awarded recognition for the magazine format is a delicious and healthy meal. Check-GM adds HomeFrees relevant health certificates, making it easy for consumers to identify healthy choices.

and certificates, many products contain HomeFrees: organic, which is a good source of whole grains, pareve kosher, vegetarian and gluten-free, and in addition, the home free ways to have a heart health, blood sugar is low, and low in sodium, and to meet the SB – 12 Dietary Guidelines for in schools. Now you can find in addition to the consumer to verify that the project has not been genetically modified to seal the boxes are home free kitchen. The products were always HomeFrees GM, but this additional step will now be home free to join and support the plan. The project is the only non-GM third-party verification available in the United States and Canada to strict best practice to avoid genetically modified organisms (GMOs).

Founder and President, and

Home Free, Jill Robbins, is an avid supporter of food allergy, which binds the community the opportunity to continue making the control of genetically modified organisms in the project. Mother of a child suffering from food allergies, that bothers me is that there is currently no reliable and definitive tests that can predict whether a protein in genetically modified foods could cause allergic reactions. Development of high sensitivity HomeFrees extraordinary charge, it was important for us not only to source components without cross-sensitivity to pollution, as well as components that are a source of GM

sources and labeling of GMOs, free home with more than 90% of Americans (http://justlabelit.org/why-label), who want the government to require labels on genetically modified foods. According to several recent polls published justlabelit.org said the majority of consumers in North America, who were asked said they would not buy food that is genetically modified. Will consumers who want the information to make these opportunities to visit nongmoproject.org and those who wish to support the latest definition, and can only go to the campaign justlabelit.org (http://www.justlabelit.org) to join the online petition FDA, which currently includes more than 500,000 unique gift to support mandatory labeling of foods, with a view to one million this spring.

Home Free and

, LLC, a manufacturer of delicious, all natural or organic, ready-to-eat cakes, whole grains, and coffee cakes free of common food allergens including peanuts, nuts, eggs and dairy products. With a commitment to the highest safety of the product, its components and sources of free home with great care and sensitivity tests on the components and amounts of random products. Home Free and businesses owned by women (http://www.wbenc.org/) and Company B are supported? (HTTP: / / www.bcorporation.net/) its commitment to social responsibility, environmental and headquartered in Windham, New Hampshire. Home Free cookies are scattered throughout North America, recent product launches in Southern California and Canada.

Jill Robbins in

, mother and Clinical Psychology, and bread, when his son was diagnosed with food allergies because of three years. After the formation of allergen free bread: Bread pleasures all the time and the foundations of Home Free, LLC, Jill Robbins focuses on a solution to the social aspect of food allergies, so that children and adults who suffer from allergies can participate fully in school activities and social development when treats are made possible allergens. For more information, please visit homefreetreats.com (http://www.homefreetreats.com) or contact via Facebook (http://www.facebook.com/HomeFreeTreats) and Twitter (http://www.twitter.com/HomeFreeTreats).

###

ALK-Abell, making GRAZAX?, Welcome GA2LEN New Hay Fever and Asthma Campaign

ALK-Abelló, making GRAZAX ®, Welcome GA2LEN New Hay Fever and Asthma Campaign

Hørsholm, Denmark (PRWeb) April 30, 2007

ALK-Abelló (http://www.alk-abello.com) today welcomed the information campaign from the Global Allergy and Asthma European Network, GA2LEN, entitled ‘What is Rhinitis lead to Asthma? “Launched last week at the Annual Conference of the network in London, UK.

campaign is based on scientific peer-reviewed publication of the appraisal committee GA2LEN and follow international guidelines on the management proposals Allergy Rhinitis and its impact on Asthma (ARIA).

ALK-Abelló

support the campaign goal of health professionals and patients should be aware of the relationship between rhinitis (also known as hay fever) and asthma and allergy march.

It is well known that a person suffering from allergies have an increased risk of developing more allergies and asthma – incidence of so-called “allergic march”. Allergic march describes the progress in the clinical manifestations of allergy, in this case the development of rhinoconjunctivitis to asthma.

Thus, some adults and children with one type of allergy, such as grass pollen (the most common), it will progress to more allergies and / or asthma later in life. Thus, the development of allergic diseases can be life-struggle.

International

Manual recommends treating allergies and keeping a watchful eye out on other symptoms associated with lower respiratory tract disease. While there are several modalities of treatment, symptomatic medications (eg antihistamines and local steroids) aim only temporarily control the symptoms of allergic diseases but does not cure the root causes of the disease.

Only

immunotherapy targets the underlying allergic disease, with the potential to produce long-term remission.

Several controlled clinical studies showed an added benefit of immunotherapy in treating asthma symptoms in patients suffering from allergic asthma, and in preventing the development of new allergies and asthma.

In particular, recent studies show that sublingual (under the tongue) immunotherapy for three years not only improve the symptoms of seasonal rhinitis but also reduce the development of seasonal asthma in children with fever.

Recently ALK-Abelló launched GRAZAX ®, the first allergy tablet that treats the cause of grass pollen allergy and not just the symptoms. It works like a vaccine to induce protective immune response, which reduces and potentially stop an allergic reaction to grass pollen.

While long-term studies are being conducted on GRAZAX ®, recently at the American Academy of Allergy, Asthma & Immunology (AAAAI 2007) congress, ALK-Abelló presented top-line results from the second year in a long-term treatment study with GRAZAX ®. In this study GRAZAX ® shows a significant success and progressive immunological changes over two years of continuous treatment. These results support the expectations of the progressive effects of long-term treatment with GRAZAX ® and the potential to stop the allergy march.

About GRAZAX ®

Grass pollen allergy is a health problem representing a significant social burden. At least 45 million people in Europe suffer from grass pollen allergy in allergic rhinitis (hay fever) or allergic asthma – or both.

majority of patients are offered only eliminate the symptoms, drugs that reduce symptoms temporarily but does not cure the allergy itself. In addition, 60-68% of patients using the medication eliminates the symptoms, assuming they are in the range of ‘not at all effective’ to ‘somewhat effective’ on individual symptoms, according to a survey conducted by the European Federation of Allergy and Airway Diseases Patients Associations (EFA ).

GRAZAX ® is, rapidly dissolving tablet once a day based allergy vaccine for patient home administration

efficacy and safety of GRAZAX ® has been documented in clinical research program ever conducted in allergy vaccination. Research shows, among other things, that the success of GRAZAX ® starts from the first day of the first grass pollen season under treatment, and that 82% of patients treated with GRAZAX ® feel ‘better’ or ‘better’ in the first treatment season compared with the previous season. More information can be found in http://www.GRAZAX.com.

About ALK-Abelló

ALK-Abelló
devoted to improving the lives of people with allergies by developing pharmaceutical products that target the cause of their allergic disease. ALK-Abelló is the world leader in the development of medical immunotherapy – a unique treatment that induces a protective immune response to prevent ongoing symptoms. Allergy immunotherapy is traditionally conducted as subcutaneous injections or sublingual droplets. ALK-Abelló aims to extend the use of immunotherapy by introducing convenient tablets for home treatment, so that more patients a causal allergy treatment offers. ALK-Abelló has more than 1,300 employees with subsidiaries, production facilities and distributors throughout the world. The company is headquartered in Hørsholm, Denmark and listed in Copenhagen Stock Exchange. More information can be found in http://www.alk-abello.com.

For more information, please contact:

Sharmi Albrechtsen, International Brand Communication Manager, ALK-Abelló Phone +45 45747555

Jacob Frische, Director, ALK-Abelló Group Communications Phone +45 45747551 or +45 22247551

GRAZAX ® is a trademark owned by ALK-Abelló A /

S.

###

© Copyright 1997 -
, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.